Canakinumab in patients with COVID-19 and type 2 diabetes - A multicentre, randomised, double-blind, placebo-controlled trial.
COVID-19
Diabetes
IL-1beta
Inflammasome
Obesitiy
Journal
EClinicalMedicine
ISSN: 2589-5370
Titre abrégé: EClinicalMedicine
Pays: England
ID NLM: 101733727
Informations de publication
Date de publication:
Nov 2022
Nov 2022
Historique:
received:
16
04
2022
revised:
12
08
2022
accepted:
12
08
2022
entrez:
21
9
2022
pubmed:
22
9
2022
medline:
22
9
2022
Statut:
epublish
Résumé
Patients with type 2 diabetes and obesity have chronic activation of the innate immune system possibly contributing to the higher risk of hyperinflammatory response to SARS-CoV2 and severe COVID-19 observed in this population. We tested whether interleukin-1β (IL-1β) blockade using canakinumab improves clinical outcome. CanCovDia was a multicenter, randomised, double-blind, placebo-controlled trial to assess the efficacy of canakinumab plus standard-of-care compared with placebo plus standard-of-care in patients with type 2 diabetes and a BMI > 25 kg/m Between October 17, 2020, and May 12, 2021, 116 patients were randomly assigned with 58 in each group. One participant dropped out in each group for the primary analysis. At the time of randomization, 85 patients (74·6 %) were treated with dexamethasone. The win-ratio of canakinumab vs placebo was 1·08 (95 % CI 0·69-1·69; p = 0·72). During four weeks, in the canakinumab vs placebo group 4 (7·0%) vs 7 (12·3%) participants died, 11 (20·0 %) vs 16 (28·1%) patients were on ICU, 12 (23·5 %) vs 11 (21·6%) were hospitalised for more than 3 weeks, respectively. Median ventilation time at four weeks in the canakinumab vs placebo group was 10 [IQR 6.0, 16.5] and 16 days [IQR 14.0, 23.0], respectively. There was no statistically significant difference in HbA1c after four weeks despite a lower number of anti-diabetes drug administered in patients treated with canakinumab. Finally, high-sensitive CRP and IL-6 was lowered by canakinumab. Serious adverse events were reported in 13 patients (11·4%) in each group. In patients with type 2 diabetes who were hospitalised with COVID-19, treatment with canakinumab in addition to standard-of-care did not result in a statistically significant improvement of the primary composite outcome. Patients treated with canakinumab required significantly less anti-diabetes drugs to achieve similar glycaemic control. Canakinumab was associated with a prolonged reduction of systemic inflammation. Swiss National Science Foundation
Sections du résumé
Background
UNASSIGNED
Patients with type 2 diabetes and obesity have chronic activation of the innate immune system possibly contributing to the higher risk of hyperinflammatory response to SARS-CoV2 and severe COVID-19 observed in this population. We tested whether interleukin-1β (IL-1β) blockade using canakinumab improves clinical outcome.
Methods
UNASSIGNED
CanCovDia was a multicenter, randomised, double-blind, placebo-controlled trial to assess the efficacy of canakinumab plus standard-of-care compared with placebo plus standard-of-care in patients with type 2 diabetes and a BMI > 25 kg/m
Findings
UNASSIGNED
Between October 17, 2020, and May 12, 2021, 116 patients were randomly assigned with 58 in each group. One participant dropped out in each group for the primary analysis. At the time of randomization, 85 patients (74·6 %) were treated with dexamethasone. The win-ratio of canakinumab vs placebo was 1·08 (95 % CI 0·69-1·69; p = 0·72). During four weeks, in the canakinumab vs placebo group 4 (7·0%) vs 7 (12·3%) participants died, 11 (20·0 %) vs 16 (28·1%) patients were on ICU, 12 (23·5 %) vs 11 (21·6%) were hospitalised for more than 3 weeks, respectively. Median ventilation time at four weeks in the canakinumab vs placebo group was 10 [IQR 6.0, 16.5] and 16 days [IQR 14.0, 23.0], respectively. There was no statistically significant difference in HbA1c after four weeks despite a lower number of anti-diabetes drug administered in patients treated with canakinumab. Finally, high-sensitive CRP and IL-6 was lowered by canakinumab. Serious adverse events were reported in 13 patients (11·4%) in each group.
Interpretation
UNASSIGNED
In patients with type 2 diabetes who were hospitalised with COVID-19, treatment with canakinumab in addition to standard-of-care did not result in a statistically significant improvement of the primary composite outcome. Patients treated with canakinumab required significantly less anti-diabetes drugs to achieve similar glycaemic control. Canakinumab was associated with a prolonged reduction of systemic inflammation.
Funding
UNASSIGNED
Swiss National Science Foundation
Identifiants
pubmed: 36128334
doi: 10.1016/j.eclinm.2022.101649
pii: S2589-5370(22)00379-0
pmc: PMC9481336
doi:
Banques de données
ClinicalTrials.gov
['NCT04510493']
Types de publication
Journal Article
Langues
eng
Pagination
101649Informations de copyright
© 2022 The Author(s).
Déclaration de conflit d'intérêts
MYD is listed as the inventor on a patent filed in 2003 for the use of an IL-1 receptor antagonist for the treatment of or prophylaxis for type 2 diabetes. JMM owns stocks of Novartis AG. DLB received consulting fees from Gilead, MSD and ViiiV, and honoraria from Abbvie, Gilead, MSD and ViiV. HFG received payments for participation to advisory boards from Merck, Gilead Sciences, Novartis, Jansen, ViiV and GSK.
Références
Diabetes Care. 2004 Mar;27(3):699-703
pubmed: 14988288
BMC Public Health. 2021 Aug 4;21(1):1505
pubmed: 34348687
Nat Rev Endocrinol. 2021 Mar;17(3):135-149
pubmed: 33479538
Diabetes Obes Metab. 2022 Jun;24(6):1176-1179
pubmed: 35112782
J Immunol. 2021 Apr 1;206(7):1569-1575
pubmed: 33547169
Cell Metab. 2013 Jun 4;17(6):851-859
pubmed: 23747244
Lancet Rheumatol. 2021 Oct;3(10):e690-e697
pubmed: 34396156
Diabetes Obes Metab. 2012 Dec;14(12):1088-96
pubmed: 22726220
Nat Rev Immunol. 2021 Nov;21(11):694-703
pubmed: 34373622
PLoS Med. 2019 Sep 12;16(9):e1002901
pubmed: 31513665
Gesundheitswesen. 2005 Aug;67 Suppl 1:S115-21
pubmed: 16032528
N Engl J Med. 2021 Feb 11;384(6):497-511
pubmed: 33264556
Lancet. 2018 Jan 27;391(10118):319-328
pubmed: 29146124
N Engl J Med. 2020 May 7;382(19):1787-1799
pubmed: 32187464
Immunity. 2022 Jan 11;55(1):31-55
pubmed: 35021057
Diabetes Care. 2021 Dec;44(12):2645-2655
pubmed: 34625431
Biology (Basel). 2021 Dec 24;11(1):
pubmed: 35053020
Cell Metab. 2020 Jun 2;31(6):1068-1077.e3
pubmed: 32369736
Am J Cardiol. 2010 May 15;105(10):1371-1377.e1
pubmed: 20451681
Circulation. 2019 Mar 5;139(10):1289-1299
pubmed: 30586730
Nat Immunol. 2017 Jul 19;18(8):826-831
pubmed: 28722720
Eur Respir J. 2020 Jul 2;56(1):
pubmed: 32398306
Endocr Rev. 2019 Aug 1;40(4):1080-1091
pubmed: 31127805
Eur Heart J. 2012 Jan;33(2):176-82
pubmed: 21900289
Medicine (Baltimore). 2019 Feb;98(7):e14587
pubmed: 30762811
Diabetes Care. 2013 Aug;36(8):2239-46
pubmed: 23514733
Physiology (Bethesda). 2009 Dec;24:325-31
pubmed: 19996363
Nat Med. 2021 Oct;27(10):1752-1760
pubmed: 34480127
Circ Heart Fail. 2017 Nov;10(11):
pubmed: 29141858
Nat Rev Drug Discov. 2014 Jun;13(6):465-76
pubmed: 24854413
Diabetes Care. 2012 Aug;35(8):1654-62
pubmed: 22699287
Nat Rev Immunol. 2019 Dec;19(12):734-746
pubmed: 31501536
N Engl J Med. 2007 Apr 12;356(15):1517-26
pubmed: 17429083
N Engl J Med. 2017 Sep 21;377(12):1119-1131
pubmed: 28845751
Lancet Diabetes Endocrinol. 2021 Jun;9(6):350-359
pubmed: 33932335
Am J Cardiol. 2015 Feb 1;115(3):288-92
pubmed: 25482680
Nature. 2017 Feb 8;542(7640):177-185
pubmed: 28179656
Nat Rev Immunol. 2011 Feb;11(2):98-107
pubmed: 21233852
Diabetes Care. 2009 Mar;32(3):421-3
pubmed: 19073760
N Engl J Med. 2001 Jun 28;344(26):1959-65
pubmed: 11430324
Int J Infect Dis. 2021 Mar;104:433-440
pubmed: 33385581
Clin Cardiol. 2018 Aug;41(8):1004-1008
pubmed: 30033595
Cell. 2018 Jan 11;172(1-2):22-40
pubmed: 29328913
FASEB J. 2019 Aug;33(8):8865-8877
pubmed: 31034780
Sci Rep. 2020 Dec 11;10(1):21775
pubmed: 33311551
Lancet Diabetes Endocrinol. 2020 Oct;8(10):823-833
pubmed: 32798471
JAMA. 2001 Jul 18;286(3):327-34
pubmed: 11466099
Lancet Rheumatol. 2020 Jun;2(6):e325-e331
pubmed: 32501454